Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yiding Chen

Showing results (121-130 of 133) with videos related to

Pageof 14
Sort By:
Journal of Hematology & Oncology|January 19, 2021
Prevalence and reclassification of BRCA1 and BRCA2 variants in a large, unselected Chinese Han breast cancer cohortYun Liu, Honglian Wang, Xin Wang, et al.
BMC Cancer|May 27, 2025
Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in ChinaBenlong Yang, Zhengkui Sun, Quchang Ouyang, et al.
JMIR Public Health and Surveillance|December 7, 2023
Safety of COVID-19 Vaccination in Patients With Breast Cancer: Cross-Sectional Study in ChinaShaohua Zhang, Jianbin Li, Ruonan Xu, et al.
Cancer Medicine|April 26, 2022
Treatment patterns, effectiveness, and patient-reported outcomes of palbociclib therapy in Chinese patients with advanced breast cancer: A multicenter ambispective real-world studyLesang Shen, Jun Zhou, Yiding Chen, et al.
Medcomm|October 13, 2025
Efficacy, Safety, and Biomarkers of Neoadjuvant Dalpiciclib (CDK4/6 inhibitor) plus Aromatase Inhibitors in Operable HER2-Negative Luminal B Breast Cancer: A Prospective, Single-Center, Single-Arm, Phase II Trial (DANCER)Yunxiang Zhou, Zhiyun Zhang, Huihui Chen, et al.
Breast Cancer Research and Treatment|December 2, 2022
Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II studyBinghe Xu, Tao Sun, Yanxia Shi, et al.
Nature Communications|March 6, 2026
Fragmentomic liquid biopsy enables early breast cancer detection, molecular subtyping and lymph node assessmentYuxuan Zhu, Siwei Zheng, Yinkuan Shao, et al.
Eclinicalmedicine|September 29, 2020
Suboptimal declines and delays in early breast cancer treatment after COVID-19 quarantine restrictions in China: A national survey of 8397 patients in the first quarter of 2020Jianbin Li, Haibo Wang, Cuizhi Geng, et al.
Nature|January 28, 2022
Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variantsKang Wang, Zijing Jia, Linilin Bao, et al.
Breast Cancer Research : BCR|May 6, 2025
8MW0511, a novel, long-acting granulocyte-colony stimulating factor fusion protein for the prevention of chemotherapy-induced neutropenia: final results from the phase III clinical trialBiyun Wang, Xiuchun Chen, Hongtao Li, et al.
Pageof 14

Showing results (121-130 of 133) with videos related to

Sort By:
Pageof 14
Journal of Hematology & Oncology|January 19, 2021
Prevalence and reclassification of BRCA1 and BRCA2 variants in a large, unselected Chinese Han breast cancer cohortYun Liu, Honglian Wang, Xin Wang, et al.
BMC Cancer|May 27, 2025
Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in ChinaBenlong Yang, Zhengkui Sun, Quchang Ouyang, et al.
JMIR Public Health and Surveillance|December 7, 2023
Safety of COVID-19 Vaccination in Patients With Breast Cancer: Cross-Sectional Study in ChinaShaohua Zhang, Jianbin Li, Ruonan Xu, et al.
Cancer Medicine|April 26, 2022
Treatment patterns, effectiveness, and patient-reported outcomes of palbociclib therapy in Chinese patients with advanced breast cancer: A multicenter ambispective real-world studyLesang Shen, Jun Zhou, Yiding Chen, et al.
Medcomm|October 13, 2025
Efficacy, Safety, and Biomarkers of Neoadjuvant Dalpiciclib (CDK4/6 inhibitor) plus Aromatase Inhibitors in Operable HER2-Negative Luminal B Breast Cancer: A Prospective, Single-Center, Single-Arm, Phase II Trial (DANCER)Yunxiang Zhou, Zhiyun Zhang, Huihui Chen, et al.
Breast Cancer Research and Treatment|December 2, 2022
Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II studyBinghe Xu, Tao Sun, Yanxia Shi, et al.
Nature Communications|March 6, 2026
Fragmentomic liquid biopsy enables early breast cancer detection, molecular subtyping and lymph node assessmentYuxuan Zhu, Siwei Zheng, Yinkuan Shao, et al.
Eclinicalmedicine|September 29, 2020
Suboptimal declines and delays in early breast cancer treatment after COVID-19 quarantine restrictions in China: A national survey of 8397 patients in the first quarter of 2020Jianbin Li, Haibo Wang, Cuizhi Geng, et al.
Nature|January 28, 2022
Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variantsKang Wang, Zijing Jia, Linilin Bao, et al.
Breast Cancer Research : BCR|May 6, 2025
8MW0511, a novel, long-acting granulocyte-colony stimulating factor fusion protein for the prevention of chemotherapy-induced neutropenia: final results from the phase III clinical trialBiyun Wang, Xiuchun Chen, Hongtao Li, et al.
Pageof 14